Form 4: Apellis Pharmaceuticals CFO Timothy Sullivan Reports Stock Transactions

Apellis Pharmaceuticals' Chief Financial Officer, Timothy Sullivan, reported the sale of 1,730 shares and the acquisition of 45,929 restricted stock units.

Summary

• Timothy Sullivan, the Chief Financial Officer of Apellis Pharmaceuticals, reported several transactions involving the company's stock.
• On January 17, 2025, Mr. Sullivan sold 1,730 shares of common stock at a price of $29.9582 per share.
• This sale was to cover tax withholding obligations related to restricted stock units.
• On January 21, 2025, Mr. Sullivan was granted 45,929 restricted stock units.
• These restricted stock units vest 25% annually over four years from the grant date, contingent on continued service.
• Mr. Sullivan also has 70,396 shares held indirectly through The Timothy E Sullivan Irrevocable Trust of 2023.

Sentiment

Score: 5

Explanation: The document reflects routine stock transactions by a company executive, which is neither positive nor negative in itself.

Industry Context

This is a routine filing related to stock transactions by a company executive, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock transactions by executives are a normal part of compensation and equity management in publicly traded companies.
• The vesting schedule of the restricted stock units is typical for executive compensation packages.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Apellis Pharmaceuticals, stock transactions, restricted stock units, insider trading, Form 4, Timothy Sullivan, CFO, equity